Reporting highlights tirzepatide's interaction with oral contraceptives
Mounjaro and Zepbound labels warn that tirzepatide can lower the effectiveness of birth control pills around dose starts and increases, and reports of unplanned pregnancies have drawn wider attention to the issue.
Labels for Mounjaro and Zepbound, both brand names for the drug tirzepatide, state that the medication can reduce how well oral birth control pills work. The warning applies specifically around the time a patient starts the drug and after each dose increase [1]. The labels advise patients to use a backup method of contraception, or switch to a non-oral method, for four weeks after starting treatment and for four weeks after every dose increase [1].
The issue got wide media coverage after reports surfaced of unplanned pregnancies in patients who were taking Mounjaro along with birth control pills [1]. Doctors have said the drug can reduce absorption of oral contraceptives in the gut, which is the likely reason the pill's effectiveness can drop during these windows [1].
Despite the label warning, coverage noted that many doctors may not be routinely counseling patients about this interaction [1]. Some doctors interviewed recommend that patients take their birth control pill and their tirzepatide injection at least one hour apart, while others suggest starting a backup method, such as condoms, several weeks before beginning the medication [1].
Several questions remain open. It is not clear whether other hormonal birth control methods, such as the patch, carry the same risk of reduced effectiveness [1]. It is also not clear whether semaglutide medications, sold as Ozempic, Wegovy, and Rybelsus, carry a similar interaction with oral contraceptives [1]. The sourced reporting does not address orforglipron, sold as Foundayo, on this point.
Why it matters for patients
Anyone taking Mounjaro or Zepbound who also relies on birth control pills faces a window of reduced contraceptive protection tied to specific moments in treatment: the start of the drug and each time the dose goes up [1]. Because tirzepatide dosing is typically increased in steps over time, this is not a one-time issue but something that can recur with each dose change [1].
The label already tells patients to use a backup method or a non-oral method for four weeks in these situations [1], but the reporting suggests that this advice is not always communicated clearly by prescribers [1]. That gap between the label and doctor-patient conversations appears to be a central reason unplanned pregnancies have occurred and drawn media attention [1].
The uncertainty about whether the patch or semaglutide drugs carry the same risk means patients using those products cannot assume the same warning applies to them, based on what is currently known from these sources [1]. This is an area where the sourced reporting says the science is not settled.
What happens next
The sources reviewed here do not include a specific date for further regulatory guidance or updated labeling. What is documented is that, as of this reporting, the Mounjaro and Zepbound labels carry the four-week backup contraception instructions tied to treatment start and dose increases [1], and that awareness of the interaction has been spreading through media coverage following reports of unplanned pregnancies [1]. Whether label updates, formal studies of the patch, or study of semaglutide's effect on oral contraceptives will follow is not addressed in the available sources.
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.